IBDEI1DF ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24293,2)
 ;;=^266994
 ;;^UTILITY(U,$J,358.3,24294,0)
 ;;=155.0^^136^1487^26
 ;;^UTILITY(U,$J,358.3,24294,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24294,1,1,0)
 ;;=1^155.0
 ;;^UTILITY(U,$J,358.3,24294,1,2,0)
 ;;=2^LIVER CANCER
 ;;^UTILITY(U,$J,358.3,24294,2)
 ;;=^73526
 ;;^UTILITY(U,$J,358.3,24295,0)
 ;;=200.60^^136^1487^28
 ;;^UTILITY(U,$J,358.3,24295,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24295,1,1,0)
 ;;=1^200.60
 ;;^UTILITY(U,$J,358.3,24295,1,2,0)
 ;;=2^LYMPHOMA,ANAPLASTIC LARGE CELL,UNSPEC
 ;;^UTILITY(U,$J,358.3,24295,2)
 ;;=^335299
 ;;^UTILITY(U,$J,358.3,24296,0)
 ;;=200.20^^136^1487^29
 ;;^UTILITY(U,$J,358.3,24296,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24296,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,24296,1,2,0)
 ;;=2^LYMPHOMA,BURKITT'S,UNSPEC
 ;;^UTILITY(U,$J,358.3,24296,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,24297,0)
 ;;=201.90^^136^1487^30
 ;;^UTILITY(U,$J,358.3,24297,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24297,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,24297,1,2,0)
 ;;=2^LYMPHOMA,HODGKIN'S,UNSPEC
 ;;^UTILITY(U,$J,358.3,24297,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,24298,0)
 ;;=200.70^^136^1487^31
 ;;^UTILITY(U,$J,358.3,24298,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24298,1,1,0)
 ;;=1^200.70
 ;;^UTILITY(U,$J,358.3,24298,1,2,0)
 ;;=2^LYMPHOMA,LARGE CELL,UNSPEC
 ;;^UTILITY(U,$J,358.3,24298,2)
 ;;=^335300
 ;;^UTILITY(U,$J,358.3,24299,0)
 ;;=200.40^^136^1487^32
 ;;^UTILITY(U,$J,358.3,24299,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24299,1,1,0)
 ;;=1^200.40
 ;;^UTILITY(U,$J,358.3,24299,1,2,0)
 ;;=2^LYMPHOMA,MANTLE CELL,UNSPEC
 ;;^UTILITY(U,$J,358.3,24299,2)
 ;;=^335297
 ;;^UTILITY(U,$J,358.3,24300,0)
 ;;=200.30^^136^1487^33
 ;;^UTILITY(U,$J,358.3,24300,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24300,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,24300,1,2,0)
 ;;=2^LYMPHOMA,MARGINAL ZONE,UNSPEC
 ;;^UTILITY(U,$J,358.3,24300,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,24301,0)
 ;;=200.50^^136^1487^35
 ;;^UTILITY(U,$J,358.3,24301,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24301,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,24301,1,2,0)
 ;;=2^LYMPHOMA,PRIM CTR NERVOUS SYS,UNSPEC
 ;;^UTILITY(U,$J,358.3,24301,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,24302,0)
 ;;=202.90^^136^1487^34
 ;;^UTILITY(U,$J,358.3,24302,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24302,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,24302,1,2,0)
 ;;=2^LYMPHOMA,OTH SITE,UNSPEC
 ;;^UTILITY(U,$J,358.3,24302,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,24303,0)
 ;;=200.10^^136^1487^36
 ;;^UTILITY(U,$J,358.3,24303,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24303,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,24303,1,2,0)
 ;;=2^LYMPHOSARCOMA,UNSPEC
 ;;^UTILITY(U,$J,358.3,24303,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,24304,0)
 ;;=172.9^^136^1487^40
 ;;^UTILITY(U,$J,358.3,24304,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24304,1,1,0)
 ;;=1^172.9
 ;;^UTILITY(U,$J,358.3,24304,1,2,0)
 ;;=2^MALIGNANT MELANOMA
 ;;^UTILITY(U,$J,358.3,24304,2)
 ;;=^75462
 ;;^UTILITY(U,$J,358.3,24305,0)
 ;;=199.0^^136^1487^16
 ;;^UTILITY(U,$J,358.3,24305,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24305,1,1,0)
 ;;=1^199.0
 ;;^UTILITY(U,$J,358.3,24305,1,2,0)
 ;;=2^DISSEMINATED CANCER
 ;;^UTILITY(U,$J,358.3,24305,2)
 ;;=^267340
 ;;^UTILITY(U,$J,358.3,24306,0)
 ;;=203.00^^136^1487^44
 ;;^UTILITY(U,$J,358.3,24306,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,24306,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,24306,1,2,0)
 ;;=2^MULTIPLE MYELOMA w/o REM
 ;;^UTILITY(U,$J,358.3,24306,2)
 ;;=^336847
 ;;^UTILITY(U,$J,358.3,24307,0)
 ;;=238.75^^136^1487^45
 ;;
 ;;$END ROU IBDEI1DF
